LivaNova (NASDAQ:LIVN) Sets New 12-Month High – Still a Buy?

Shares of LivaNova PLC (NASDAQ:LIVN) reached a new 52-week high during trading on Thursday . The company traded as high as $72.92 and last traded at $72.00, with a volume of 6404 shares traded. The stock had previously closed at $72.44.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on LIVN. Mizuho upped their price target on shares of LivaNova from $85.00 to $90.00 and gave the company an “outperform” rating in a research note on Thursday, May 7th. Barclays boosted their price objective on shares of LivaNova from $73.00 to $76.00 and gave the company an “equal weight” rating in a report on Thursday, May 7th. Needham & Company LLC upped their target price on LivaNova from $64.00 to $81.00 and gave the company a “buy” rating in a research report on Wednesday, February 25th. Stifel Nicolaus set a $80.00 target price on LivaNova in a research note on Wednesday, February 25th. Finally, Piper Sandler reiterated an “overweight” rating and set a $85.00 price target on shares of LivaNova in a research note on Thursday, February 19th. Seven equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, LivaNova presently has an average rating of “Moderate Buy” and an average target price of $77.22.

LivaNova Stock Down 0.6%

The company has a current ratio of 1.33, a quick ratio of 1.11 and a debt-to-equity ratio of 0.24. The business’s 50-day simple moving average is $64.09 and its 200-day simple moving average is $62.63. The company has a market capitalization of $3.96 billion, a PE ratio of 36.91 and a beta of 0.82.

LivaNova (NASDAQ:LIVN) last released its quarterly earnings data on Wednesday, May 6th. The company reported $0.98 earnings per share for the quarter, topping analysts’ consensus estimates of $0.85 by $0.13. LivaNova had a net margin of 7.48% and a return on equity of 16.48%. The firm had revenue of $362.26 million for the quarter, compared to analyst estimates of $346.05 million. During the same quarter in the prior year, the business earned $0.88 earnings per share. The business’s quarterly revenue was up 14.3% compared to the same quarter last year. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS. As a group, equities research analysts anticipate that LivaNova PLC will post 3.68 EPS for the current fiscal year.

Hedge Funds Weigh In On LivaNova

A number of institutional investors have recently modified their holdings of LIVN. UMB Bank n.a. boosted its stake in shares of LivaNova by 22.6% in the fourth quarter. UMB Bank n.a. now owns 971 shares of the company’s stock worth $60,000 after buying an additional 179 shares during the last quarter. State of Michigan Retirement System raised its position in LivaNova by 1.5% during the first quarter. State of Michigan Retirement System now owns 13,111 shares of the company’s stock valued at $833,000 after acquiring an additional 200 shares in the last quarter. Hantz Financial Services Inc. raised its position in LivaNova by 159.9% during the fourth quarter. Hantz Financial Services Inc. now owns 434 shares of the company’s stock valued at $27,000 after acquiring an additional 267 shares in the last quarter. Arizona State Retirement System lifted its holdings in LivaNova by 1.7% in the third quarter. Arizona State Retirement System now owns 16,129 shares of the company’s stock valued at $845,000 after acquiring an additional 274 shares during the period. Finally, Parallel Advisors LLC lifted its holdings in LivaNova by 28.8% in the fourth quarter. Parallel Advisors LLC now owns 1,266 shares of the company’s stock valued at $78,000 after acquiring an additional 283 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

About LivaNova

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.